Clinical Trials Logo

Clinical Trial Summary

In this phase II study, eligible patients will be treated with maximal tumor resection and then started treatment within 8 weeks. Chemotherapy, Nivolumab and radiotherapy (RT) will be started on day one. Chemotherapy will be administered weekly during radiotherapy. Radiotherapy will be performed from Monday to Friday for five weeks. Nivolumab will be administered for one year (13 infusions). Patients will have the complete tumour assessment by computed tomography scan (CT-scan) and cystoscopy up to 5 years after radiotherapy.


Clinical Trial Description

The screening phase is up to six weeks before the beginning of treatment. The treatment phase is from the day one of therapy until 30 days after the last patient last cycle. During the treatment phase each patient will be treated with concomitant chemo-radiotherapy for up to five weeks. The first day of radiotherapy is considered the first day of treatment in the study and cisplatin, nab-paclitaxel and nivolumab will be administered. Cisplatin and nab paclitaxel will be administered weekly during radiotherapy for a maximum of five infusions. Nivolumab will be administered at a flat dose of 480 mg every four weeks for 13 cycles. After the end of radio-chemotherapy patients will be followed every four weeks until the end of nivolumab treatment of up to 13 cycles. Radiological assessment with whole body (abdominal/pelvic/chest) CT-scan or CT-scan of the thorax and abdominal magnetic resonance imaging (MRI). This will be performed every 16 weeks (±2 weeks) after the post radio/chemotherapy evaluation for the first two years and every six months (±2 weeks) up to 5 years. After five years patients will be followed as per local clinical practice. At the time of radiographic disease progression, patients exit from the study and will be managed as per local guidelines. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05203913
Study type Interventional
Source Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Roberto Iacovelli, MD, PhD
Phone +390630157373
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date February 1, 2022
Completion date June 15, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05097404 - Clinical Utility of VI-RADS in Diagnosis of MIBC
Not yet recruiting NCT04966130 - Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.
Recruiting NCT04610671 - Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC Phase 1
Not yet recruiting NCT05295992 - Re-optimization Based Online Adaptive Radiotherapy of Bladder Cancer N/A
Not yet recruiting NCT05334069 - Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recruiting NCT05028660 - AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study
Not yet recruiting NCT04909775 - Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT04876313 - An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) Phase 2
Not yet recruiting NCT04686149 - a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
Recruiting NCT05221827 - Clinical Performance Evaluation of the C2i-Test
Not yet recruiting NCT04724928 - Evaluating the Impact of FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients With Muscle Invasive Bladder Cancer Phase 2
Active, not recruiting NCT04598724 - Addressing Barriers to Palliative Care Use in Bladder Cancer
Recruiting NCT04506554 - A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer Phase 2
Recruiting NCT04900558 - Robotic Radical Cystectomy Outcomes